Alexion Pharmaceuticals hast new data from an ongoing Phase 1/2 dose-escalation study of ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH), showing rapid and sustained reductions in lactate dehydrogenase (LDH), a direct marker of hemolysis (the destruction of red blood cells), in patients treated with once-monthly dosing.

ALXN1210 is a longer-acting anti-C5 antibody currently in Phase 3 trials in patients with PNH and atypical hemolytic uremic syndrome (aHUS). PNH is a debilitating, ultra-rare blood disorder characterized by complement-mediated hemolysis.